PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'BIH Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany.\', \'Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité Universitätsmedizin Berlin, Berlin, Germany.\', \'Institute of Medical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.\', \'Department of Transfusion Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.\', \'Julius Wolff Institute (JWI), Charité Universitätsmedizin Berlin, Berlin, Germany.\', \'Department of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.\', \'Berlin Center for Advanced Therapies (BECAT), All Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-of Universität zu Berlin, Berlin Institute of Health (BIH), Berlin, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2020.01091
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 32574263
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
?:title
  • MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32574263>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32574263>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all